Fan Yanghua, He Yu, Zhou Xi, Liu Yong, Wang Fu
Department of Central Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Orthopedics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China,
Cancer Manag Res. 2019 Mar 5;11:2027-2037. doi: 10.2147/CMAR.S196071. eCollection 2019.
Abnormal expression of long non-coding RNA anti-differentiation noncoding RNA () can frequently be detected in cancer. Because of this, it is of vital necessity to perform a meta-analysis to clarify the value of as a prognostic marker in malignant tumors.
Related studies were retrieved from electronic databases including Web of Science, PubMed, and OVID, from inception to November 21, 2018. The HRs and corresponding 95% CIs were also calculated to explore the relationship of expression with patient survival. Moreover, ORs were computed to assess the association of expression with the pathological parameters.
A total of 14 studies involving 1,117 patients were included in this meta-analysis. The pooled HR suggested that high expression was correlated with poor overall survival (OS; HR =1.85, 95% CI: 1.56-2.18) and disease-free survival (DFS; HR =2.49, 95% CI: 1.75-3.56) in cancer patients. Besides, High expression was related to poor histological grade (PHG; OR =2.01, 95% CI: 1.08-3.75), high tumor stage (HTS; OR =3.52, 95% CI: 1.67-7.43), lymph node metastasis (LNM; OR =3.47, 95% CI: 1.42-8.49), and distant metastasis (DM; OR =4.76, 95% CI: 2.39-9.51). However, no evidence of obvious asymmetry was found for DFS (Pr>||=0.308), PHG (Pr>||=0.707), LNM (Pr>||=0.174), and DM (Pr>||=0.734) using Begg's funnel plot.
Our findings suggest that high expression can predict poor OS, DFS, PHG, HTS, LNM, and DM in cancer patients, implying that high expression may potentially serve as a new indicator for poor prognosis and metastasis in cancer.
在癌症中经常可以检测到长链非编码RNA抗分化非编码RNA（）的异常表达。因此，进行一项荟萃分析以阐明作为恶性肿瘤预后标志物的价值至关重要。
从包括科学网、PubMed和OVID在内的电子数据库中检索从创刊到2018年11月21日的相关研究。还计算了风险比（HRs）及相应的95%置信区间（CIs），以探讨表达与患者生存的关系。此外，计算比值比（ORs）以评估表达与病理参数的关联。
本荟萃分析共纳入14项研究，涉及1117例患者。汇总的HR表明，高表达与癌症患者较差的总生存期（OS；HR =1.85，95%CI：1.56 - 2.18）和无病生存期（DFS；HR =2.49，95%CI：1.75 - 3.56）相关。此外，高表达与较差的组织学分级（PHG；OR =2.01，95%CI：1.08 - 3.75）、高肿瘤分期（HTS；OR =3.52，95%CI：1.67 - 7.43）、淋巴结转移（LNM；OR =3.47，95%CI：1.42 - 8.49）和远处转移（DM；OR =4.76，95%CI：2.39 - 9.51）有关。然而，使用Begg漏斗图分析DFS（Pr>|z| =0.308）、PHG（Pr>|z| =0.707）、LNM（Pr>|z| =0.174）和DM（Pr>|z| =0.734）时，未发现明显不对称的证据。
我们的研究结果表明，高表达可预测癌症患者较差的OS、DFS、PHG、HTS、LNM和DM，这意味着高表达可能潜在地作为癌症预后不良和转移的新指标。
